A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
Virology
; 507: 242-256, 2017 07.
Article
em En
| MEDLINE
| ID: mdl-28458036
ABSTRACT
Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
/
4_TD
Base de dados:
MEDLINE
Assunto principal:
Nicotiana
/
Vaccinia virus
/
Proteína gp41 do Envelope de HIV
/
Infecções por HIV
/
HIV-1
/
Imunização
/
Vacinas contra a AIDS
/
Produtos do Gene gag do Vírus da Imunodeficiência Humana
Tipo de estudo:
Clinical_trials
/
Evaluation_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Virology
Ano de publicação:
2017
Tipo de documento:
Article